CELZ

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.08
Percentage change -3.09	%

Peers: VXRT HOOK ATOS CLRB CYCN DYAI MBRX QLGN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.80	Insider Own	2.10%	Shs Outstand	1.75M	Perf Week	-3.09%
Market Cap	4.12M	Forward P/E	-	EPS next Y	-2.24	Insider Trans	0.00%	Shs Float	1.71M	Perf Month	-18.79%
Income	-5.32M	PEG	-	EPS next Q	-0.63	Inst Own	3.96%	Short Float	1.75%	Perf Quarter	-22.02%
Sales	0.01M	P/S	411.88	EPS this Y	15.16%	Inst Trans	-1.17%	Short Ratio	0.76	Perf Half Y	-43.66%
Book/sh	4.93	P/B	0.48	EPS next Y	29.78%	ROA	-54.82%	Short Interest	0.03M	Perf Year	-45.86%
Cash/sh	3.58	P/C	0.66	EPS next 5Y	-	ROE	-57.03%	52W Range	2.21 - 10.28	Perf YTD	-48.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	81.53%	ROI	-81.10%	52W High	-77.09%	Beta	4.93
Dividend TTM	-	Quick Ratio	19.12	Sales past 5Y	-20.62%	Gross Margin	-970.31%	52W Low	6.56%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	19.13	EPS Y/Y TTM	45.45%	Oper. Margin	-51181.51%	RSI (14)	34.19	Volatility	9.17% 8.33%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-55.28%	Profit Margin	-48345.28%	Recom	1.00	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	26.44%	Payout	-	Rel Volume	0.92	Prev Close	2.43
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-100.00%	Earnings	Nov 27	Avg Volume	39.53K	Price	2.36
SMA20	-7.13%	SMA50	-27.03%	SMA200	-39.66%	Trades		Volume	28,105	Change	-3.09%

Nov-13-24 09:00AM	Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment (GlobeNewswire)
Oct-24-24 08:21AM	Creative Medical to sell 418,552 shares at $4.42 in registered direct offering (TipRanks)
Oct-23-24 08:00AM	Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -22.57%
Jul-24-24 09:00AM	Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program (GlobeNewswire)
Jul-10-24 08:30AM	Creative Medical Technology Holdings Provides Corporate Update (GlobeNewswire)
08:30AM	Loading…
Jun-24-24 08:30AM	Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin (GlobeNewswire)
May-13-24 10:54AM	CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024 (InvestorPlace)
Mar-27-24 09:00AM	Creative Medical Technology Holdings Provides Corporate Update (Business Wire)
Mar-07-24 11:04AM	Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101 (Zacks) +32.35%
09:15AM	Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access (Business Wire)
Mar-06-24 07:00AM	Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy (Business Wire) +15.28%
Dec-20-23 09:35AM	Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain (ACCESSWIRE)
Nov-15-23 08:00AM	Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
Oct-10-23 08:00AM	Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem ('CELZ-201-DDT') Novel Cell Therapy to Treat Chronic Lower Back Pain (PR Newswire)
Sep-19-23 08:00AM	Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain (PR Newswire)
10:45AM	Loading…
Aug-24-23 10:45AM	What Is Allogeneic Cell Therapy, And Whats Driving This Markets 25%+ Annual Global Growth? (ACCESSWIRE)
Jul-13-23 09:00AM	Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update (ACCESSWIRE) -5.84%
Jun-28-23 08:00AM	Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements (PR Newswire)
Jun-12-23 08:01AM	Creative Medical Technology Announces $2 Million Share Repurchase Program (PR Newswire)
08:00AM	Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
Jun-09-23 12:30PM	Creative Medical Technology Holdings Announces Reverse Stock Split (PR Newswire) -24.96%
May-31-23 08:00AM	Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform (PR Newswire)
May-22-23 08:30AM	Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development (PR Newswire)
May-18-23 08:00AM	Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem Allogenic Cell Line (PR Newswire) -10.29%
May-14-23 08:13AM	Creative Medical Technology Holdings First Quarter 2023 Earnings: US$0.075 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
Apr-12-23 08:00AM	Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study (PR Newswire) +80.79%
Apr-04-23 08:00AM	Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update (PR Newswire)
Mar-23-23 08:00AM	Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes (PR Newswire) +5.77%
Mar-21-23 08:00AM	Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development (PR Newswire) +15.74%
Mar-07-23 08:00AM	Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201 (Business Wire)
08:00AM	Loading…
Feb-14-23 08:00AM	Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects (Business Wire) +10.82%
Feb-08-23 08:00AM	Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire) +101.04%
Nov-03-22 07:30AM	Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire) +24.84%
Oct-20-22 08:00AM	Creative Medical Technology Holdings Develops AlloStem Clinical Cell Line (PR Newswire) +5.49%
Sep-26-22 08:00AM	Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study (PR Newswire) -11.43%
Jul-28-22 07:30AM	Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study (PR Newswire) +8.53%
Jun-15-22 08:30AM	Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform (PR Newswire)
Apr-29-22 08:40AM	Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -6.00%
Apr-20-22 08:30AM	Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product (PR Newswire) +9.38%
Apr-12-22 08:30AM	Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World (PR Newswire) -7.08%
Mar-31-22 08:30AM	Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform (PR Newswire) +15.04%
Mar-23-22 08:30AM	Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study (PR Newswire) +82.35%
Mar-10-22 08:30AM	Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction (PR Newswire)
Mar-08-22 08:30AM	Creative Medical Technology to Participate in the 34th Annual Roth Conference (PR Newswire) -10.74%
Mar-02-22 08:30AM	Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer (PR Newswire)
Jan-20-22 07:15AM	Phoenix's Creative Medical Technology uplists to Nasdaq in hopes of making more stem cell treatments (American City Business Journals)
Nov-09-21 04:45PM	Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market (PR Newswire) -7.08% -6.07%
Oct-12-21 08:15AM	Creative Medical Technology Holdings Reports Positive Data on ImmCelz Immunotherapy Product (PR Newswire)
Oct-01-21 08:15AM	Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz Platform (PR Newswire) +14.00%
Sep-16-21 07:45AM	Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem® (PR Newswire) +5.06%
Aug-09-21 04:43PM	Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors (PR Newswire) +27.84%
Jul-20-21 07:45AM	Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product (PR Newswire)
Jun-22-21 07:45AM	Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance (PR Newswire)
Jun-17-21 07:00AM	Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference (PR Newswire) +6.67%
Jun-09-21 08:18AM	Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes (PR Newswire) +17.12%
May-24-21 07:45AM	Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease (PR Newswire) +10.94%
May-20-21 08:45AM	Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings (PR Newswire) +17.88%

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Creative Medical Technology Holdings Inc

Upgrade your FINVIZ experience